Equillium, Inc. (EQ)
Price:
1.82 USD
( + 0.09 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Vertex Pharmaceuticals Incorporated
VALUE SCORE:
8
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Aurinia Pharmaceuticals Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
NEWS
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
seekingalpha.com
2026-02-25 17:24:17Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting, aiming to improve efficacy and safety over broad-spectrum inhibitors like JAK/STAT signaling pathways. EQ302, an oral IL-15/IL-21 inhibitor for celiac disease, is positioned for partnering, offering potential future catalysts but remains in early discovery.
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
2026-02-25 08:30:00LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 32.2%
defenseworld.net
2026-02-04 04:35:03Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,473,443 shares, a growth of 32.2% from the December 31st total of 1,114,202 shares. Approximately 3.5% of the shares of the stock are sold
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
2026-02-02 16:05:00LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium's 2024 Inducement Plan.
Equillium to Participate in Upcoming Investor Conferences
globenewswire.com
2025-11-20 16:35:00LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
globenewswire.com
2025-11-13 16:05:00Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025.
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript
seekingalpha.com
2025-11-05 18:21:30Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, CEO & Director Stephen Connelly - Chief Scientific Officer & President Francisco Quintana Brian Gordon Feagan Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Cha Cha Yang - Jefferies LLC, Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Brian Feagan Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Min Lee - Guggenheim Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Equillium Bio Virtual KOL Event.
Equillium to Participate in Upcoming Investor Conferences
globenewswire.com
2025-11-04 08:30:00LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format: Company Presentation & 1x1 Meetings Date: Wednesday, November 12, 2025 Time: 3:20-3:50 PM EDT Jefferies Global Healthcare Conference in London Format: 1x1 Meetings Date: Tuesday, November 18 – Thursday, November 20, 2025 Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
2025-11-03 16:05:00LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium's 2024 Inducement Plan.
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
globenewswire.com
2025-10-22 08:00:00Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis
Equillium Announces Leadership and Corporate Updates
globenewswire.com
2025-10-06 16:02:00LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
globenewswire.com
2025-09-23 05:30:00SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M.
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-03 16:05:00LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Equillium to Participate in the Cantor Global Healthcare Conference 2025
businesswire.com
2025-08-29 16:03:00LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.
No data to display
Equillium: Multi-Cytokine Platform To Go Beyond Scope Of EQ504 For UC
seekingalpha.com
2026-02-25 17:24:17Equillium (EQ) remains a 'Hold' as it advances EQ504 for ulcerative colitis, with phase 1 trial initiation targeted for mid-2026. Company's Multi-Cytokine Platform enables selective cytokine targeting, aiming to improve efficacy and safety over broad-spectrum inhibitors like JAK/STAT signaling pathways. EQ302, an oral IL-15/IL-21 inhibitor for celiac disease, is positioned for partnering, offering potential future catalysts but remains in early discovery.
Equillium to Participate in the Leerink Partners 2026 Global Healthcare Conference
globenewswire.com
2026-02-25 08:30:00LA JOLLA, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside chat at the Leerink Partners 2026 Global Healthcare Conference on Wednesday, March 11, 2026 at 10:40am ET.
Short Interest in Equillium, Inc. (NASDAQ:EQ) Increases By 32.2%
defenseworld.net
2026-02-04 04:35:03Equillium, Inc. (NASDAQ: EQ - Get Free Report) was the target of a large growth in short interest during the month of January. As of January 15th, there was short interest totaling 1,473,443 shares, a growth of 32.2% from the December 31st total of 1,114,202 shares. Approximately 3.5% of the shares of the stock are sold
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
2026-02-02 16:05:00LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on January 30, 2026, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase an aggregate of 59,750 shares of common stock to two new employees under Equillium's 2024 Inducement Plan.
Equillium to Participate in Upcoming Investor Conferences
globenewswire.com
2025-11-20 16:35:00LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
globenewswire.com
2025-11-13 16:05:00Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor (AhR) in intestinal inflammation, the unmet medical need in ulcerative colitis, and the potential clinical utility of EQ504, a novel oral AhR modulator EQ504 Phase 1 clinical study initiation planned for mid-2026 LA JOLLA, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for its third fiscal quarter ended September 30, 2025.
Equillium, Inc. (EQ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases Transcript
seekingalpha.com
2025-11-05 18:21:30Equillium, Inc. ( EQ ) Discusses Aryl Hydrocarbon Receptor as a Drug Target and EQ504 Program in Immune-Mediated Diseases November 5, 2025 12:00 PM EST Company Participants Bruce Steel - Co-Founder, CEO & Director Stephen Connelly - Chief Scientific Officer & President Francisco Quintana Brian Gordon Feagan Conference Call Participants Thomas Smith - Leerink Partners LLC, Research Division Cha Cha Yang - Jefferies LLC, Research Division Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Brian Feagan Catherine Novack - JonesTrading Institutional Services, LLC, Research Division Min Lee - Guggenheim Securities, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Equillium Bio Virtual KOL Event.
Equillium to Participate in Upcoming Investor Conferences
globenewswire.com
2025-11-04 08:30:00LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Stifel Healthcare Conference Format: Company Presentation & 1x1 Meetings Date: Wednesday, November 12, 2025 Time: 3:20-3:50 PM EDT Jefferies Global Healthcare Conference in London Format: 1x1 Meetings Date: Tuesday, November 18 – Thursday, November 20, 2025 Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference.
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
2025-11-03 16:05:00LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on October 31, 2025, the Compensation Committee of Equillium's Board of Directors granted inducement awards consisting of nonstatutory stock options to purchase a total of 7,200 shares of common stock to a new employee under Equillium's 2024 Inducement Plan.
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025
globenewswire.com
2025-10-22 08:00:00Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis Virtual webinar to feature expert insights on unmet need, treatment landscape and potential clinical utility of Aryl Hydrocarbon Receptor (AhR) modulation in ulcerative colitis
Equillium Announces Leadership and Corporate Updates
globenewswire.com
2025-10-06 16:02:00LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced changes to its Board of Directors (BoD) and senior leadership, and other corporate updates.
NeuraClick Welcomes Biotech Veteran Daniel M. Bradbury as Strategic and Metabolic Programs Advisor
globenewswire.com
2025-09-23 05:30:00SAN DIEGO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- NeuraClick, Inc., an innovative, preclinical-stage biopharmaceutical company reimagining patient health through the development of novel, long-acting neurotherapeutics, today announced the appointment of industry veteran and biotech executive Daniel M.
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
businesswire.com
2025-09-03 16:05:00LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Equillium to Participate in the Cantor Global Healthcare Conference 2025
businesswire.com
2025-08-29 16:03:00LA JOLLA, Calif.--(BUSINESS WIRE)-- #AhRModulation--Equillium to Participate in the Cantor Global Healthcare Conference 2025.